Biotech predictions

38 dated questions on gene editing, longevity drugs, synthetic biology — each one answered independently by six frontier models, none of them shown the market price. Of those, 3 have passed their deadlines and been graded against cited sources.

Biotech predictions

The FDA approves AbbVie's Biologics License Application for etentamig.

A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.

Standard clinical turnaround for an ex vivo autologous gene editing therapy falls below 14 days before 2030.

An in vivo CRISPR gene editing therapy receives standard FDA approval before 2028.

Human germline gene editing results in a live birth before 2030.

Cedars-Sinai reports that microgravity improved the production of stem-cell-derived structures from the CRS-35 mission experiments.

Genetic editing creates a distinct human subspecies before 2050.

A human life expectancy surpasses 150 years through medical intervention before 2050.

Mount Sinai's CRS-35 tissue model experiment yields publishable data on microgravity-induced aging or functional changes.

A therapeutic treatment scientifically proven to reverse cellular aging in humans receives regulatory approval before 2035.

Mount Sinai publishes findings analyzing the returned CRS-35 bioengineered brain and cardiovascular tissue models.

The first fully functional lab-grown human organ is successfully transplanted into a patient before 2030.

A fully bioengineered, lab-grown human solid organ is successfully transplanted into a human patient before 2031.

The FDA suspends or revokes approval of an approved gene-editing therapy due to off-target side effects before 2028.

The US FDA approves an in vivo CRISPR-based gene editing therapy for common cardiovascular disease before 2030.

The FDA approves a therapeutic drug with an explicit indication to slow or reverse human biological aging before 2031.

A fully lab-grown solid human organ is successfully transplanted into a human patient before 2032.

A gene therapy targeting herpes simplex virus enters Phase 3 clinical trials before 2029.

The FDA approves at least 10 novel gene therapies in a single calendar year before 2030.

A clinical trial begins treating human embryos with heritable germline gene editing before 2035.

An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before 2030.

LambdaVision begins clinical trials for its microgravity-assembled retinal implant by December 31, 2028.

An AI-designed drug candidate cures or reverses Alzheimer's pathology in human clinical trials before 2036.

Britain's MHRA publishes a regulatory roadmap for space-manufactured pharmaceuticals before the end of 2026.

The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.

The US FDA approves an in vivo CRISPR gene editing therapy before January 1, 2028.

GSK initiates a Phase III efficacy trial for FLUm3HA.b-3NA by September 30, 2026.

GSK starts a Phase III efficacy trial of FLUm3HA.b-3NA in September 2026.✓ happened

Hualan Biological Vaccine initiates clinical trials for its novel influenza mRNA vaccine.

GSK begins its Phase III efficacy trial for FLUm3HA.b-3NA in September 2026.

Novo Nordisk resumes clinical development of ziltivekimab.

The FDA lifts the clinical hold on new patient enrollment in Biohaven's epilepsy drug trials.

The FDA approves zilganersen by its September 22, 2026 PDUFA target action date.✓ happened

The FDA approves zidesamtinib by its September 18, 2026 PDUFA target action date.✓ happened